Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $48.33 Average Price Target from Analysts

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) have received an average recommendation of “Buy” from the sixteen research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and four have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $48.9167.

SRRK has been the subject of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. JPMorgan Chase & Co. boosted their price objective on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Leerink Partners started coverage on Scholar Rock in a research report on Monday, September 15th. They set an “outperform” rating and a $51.00 target price on the stock. Leerink Partnrs raised shares of Scholar Rock to a “strong-buy” rating in a report on Monday, September 15th. Finally, Piper Sandler decreased their target price on Scholar Rock from $52.00 to $51.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 24th.

Scholar Rock Stock Performance

SRRK opened at $43.90 on Friday. The firm has a fifty day moving average price of $36.44 and a 200 day moving average price of $35.49. Scholar Rock has a 1 year low of $22.71 and a 1 year high of $48.28. The stock has a market cap of $4.48 billion, a P/E ratio of -13.94 and a beta of 0.61. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the prior year, the business posted ($0.66) EPS. Equities research analysts anticipate that Scholar Rock will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Mo Qatanani sold 136,462 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $45.21, for a total value of $6,169,447.02. Following the completion of the sale, the insider owned 108,964 shares of the company’s stock, valued at approximately $4,926,262.44. This represents a 55.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Srinivas Akkaraju purchased 387,414 shares of the company’s stock in a transaction dated Friday, October 3rd. The stock was purchased at an average cost of $37.27 per share, with a total value of $14,438,919.78. Following the purchase, the director owned 387,414 shares in the company, valued at approximately $14,438,919.78. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 530,038 shares of company stock worth $19,988,928 and have sold 140,821 shares worth $6,316,638. 13.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Scholar Rock

Several large investors have recently modified their holdings of SRRK. Ramirez Asset Management Inc. acquired a new stake in shares of Scholar Rock in the third quarter valued at $37,000. Penserra Capital Management LLC purchased a new stake in Scholar Rock during the third quarter worth about $56,000. Strs Ohio acquired a new stake in Scholar Rock during the 1st quarter worth approximately $77,000. Bessemer Group Inc. boosted its position in Scholar Rock by 970.0% in the 3rd quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock valued at $86,000 after buying an additional 2,105 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new position in shares of Scholar Rock in the second quarter worth $94,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).